Evidence map›Paper›PMID 38659591›Full record

ReviewFrontiers in pharmacology2024

Metabolic vulnerability of cancer stem cells and their niche.

Laura Marrone, Simona Romano, Chiara Malasomma, Valeria Di Giacomo, Andrea Cerullo, Rosetta Abate, Marialuisa Alessandra Vecchione, Deborah Fratantonio, Maria Fiammetta Romano

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Laura MarroneDepartment of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples, Italy.
Simona RomanoDepartment of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples, Italy.
Chiara MalasommaDepartment of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples, Italy.
Valeria Di GiacomoDepartment of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples, Italy.
Andrea CerulloDepartment of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples, Italy.
Rosetta AbateDepartment of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples, Italy.
Marialuisa Alessandra VecchioneDepartment of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples, Italy.
Deborah FratantonioDepartment of Medicine and Surgery, LUM University Giuseppe Degennaro, Bari, Italy.
Maria Fiammetta RomanoDepartment of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples, Italy.
University of Naples Federico II · ITOspedale San Giuseppe · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer stem cells (CSC) are the leading cause of the failure of anti-tumor treatments. These aggressive cancer cells are preserved and sustained by adjacent cells forming a specialized microenvironment, termed niche, among which tumor-associated macrophages (TAMs) are critical players. The cycle of tricarboxylic acids, fatty acid oxidation path, and electron transport chain have been proven to play central roles in the development and maintenance of CSCs and TAMs. By improving their oxidative metabolism, cancer cells are able to extract more energy from nutrients, which allows them to survive in nutritionally defective environments. Because mitochondria are crucial bioenergetic hubs and sites of these metabolic pathways, major hopes are posed for drugs targeting mitochondria. A wide range of medications targeting mitochondria, electron transport chain complexes, or oxidative enzymes are currently investigated in phase 1 and phase 2 clinical trials against hard-to-treat tumors. This review article aims to highlight recent literature on the metabolic adaptations of CSCs and their supporting macrophages. A focus is provided on the resistance and dormancy behaviors that give CSCs a selection advantage and quiescence capacity in particularly hostile microenvironments and the role of TAMs in supporting these attitudes. The article also describes medicaments that have demonstrated a robust ability to disrupt core oxidative metabolism in preclinical cancer studies and are currently being tested in clinical trials.

Indexed as

anti-mitochondrial drugs in clinical trialscancer stem cellsoxidative metabolismtumor associated macrophagestumor dormancy

Identifiers

PMID38659591
PMCPMC11039812
OpenAlexW4394688254

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.